Table 1.
Clinical and prognostic parameters of the chronic lymphocytic leukemia (CLL) samples enrolled in this study.
| Pat. ID | Age | Gender | Rai/Binet Stage | IGHV Status | Cytogenetic Alterations | NOTCH1 Mutations | NOTCH2 GSI-R/S* |
Treatment |
|---|---|---|---|---|---|---|---|---|
| CLL1 | 76 | male | II/B | U, VH2-5 | normal | N1ΔCT | GSI-S | no |
| CLL2 | 69 | male | II/B | U, VH1-69 | normal | N1ΔCT | GSI-R | no |
| CLL3 | 70 | male | IV/C | M, VH4-34 | Tri12 | wt | ND | no |
| CLL4 | 64 | male | II/B | M, VH3-23 | 13q-, 17p- | wt | ND | no |
| CLL5 | 51 | female | IV/C | U, VH1-69 | normal | wt | ND | no |
| CLL6 | 56 | male | IV/C | M, VH3-21 | 13q-, 11q- | wt | GSI-S | no |
| CLL7 | 68 | male | II/B | M, VH3-48 | 13q-, 11q- | wt | GSI-R | no |
| CLL8 | 84 | male | I/A | NA | normal | wt | GSI-R | no |
| CLL9 | 81 | female | I/A | M, VH3-15 | 13q- | wt | GSI-R | no |
| CLL10 | 73 | female | IV/C | M, VH3-23 | normal | wt | GSI-S | no |
| CLL11 | 66 | female | I/A | M, VH3-48 | 13q- | wt | GSI-R | no |
| CLL12 | 70 | male | I/A | M, VH1-8 | 13q- | wt | GSI-R | no |
| CLL13 | 66 | female | II/B | M, VH3-23 | 13q- | wt | GSI-R | no |
| CLL14 | 75 | female | IV/C | NA | 13q- | wt | GSI-S | no |
| CLL15 | 65 | male | I/A | U, VH1-69 | 14q32- | wt | GSI-R | no |
| CLL16 | 52 | male | IV/C | U, VH1-69 | normal | wt | GSI-S | no |
| CLL17 | 55 | male | II/B | U, VH3-11 | 13q-, 11q- | wt | GSI-R | Ibrutinib |
| CLL18 | 40 | female | I/A | U, VH3-20 | normal | wt | GSI-S | no |
| CLL19 | 68 | female | III/B | U, VH1-2 | 13q- | N1ΔCT | GSI-S | no |
| CLL20 | 60 | male | IV/C | U, VH1-46 | 13q-, 11q- | N1ΔCT | GSI-S | no |
| CLL21 | 52 | male | II/B | NA | 13q- | ND | GSI-R | no |
| CLL22 | 70 | female | II/B | M, VH3-13 | 13q- | ND | GSI-S | no |
| CLL23 | 54 | male | I/A | U, VH3-53 | normal | ND | ND | no |
| CLL24 | 77 | female | IV/C | NA | 17p- | ND | ND | no |
| CLL25 | 54 | male | I/A | U, VH4-39 | 11q- | ND | ND | Duvelisib |
| CLL26 | 69 | male | II/B | U, VH3-21 | 13q- | ND | ND | Ibrutinib |
| CLL27 | 70 | male | II/B | M, VH3-13 | 13q- | ND | ND | no |
| CLL28 | 61 | female | I/A | M, VH3-7 | normal | ND | ND | no |
| CLL29 | 77 | female | II/B | M, VH3-74 | normal | ND | ND | no |
| CLL30 | 87 | female | IV/C | M, VH3-11 | 13q- | ND | ND | Idealisib |
| CLL31 | 68 | female | II/B | M, VH3-48 | 13q- | ND | ND | no |
| CLL32 | 83 | female | II/B | M, VH4-59 | 13q- | ND | ND | Ibrutinib |
| CLL33 | 60 | male | II/B | U, VH1-69 | 13q-/11q- | ND | ND | Idealisib |
33 CLL patients were matched in terms of age, gender, Rai/Binet stages, IgVH mutational status and cytogenetic aberrations. CLL1-20 were used for initial drug screening and CLL21-33 were additionally used for follow-up and validation experiments. Abbreviations: U, IGHV unmutated; M, IGHV mutated; ND, not determined; NA, not amplifiable; N1ΔCT indicates the recurrent NOTCH1 microdeletion; wt indicates wild type. NOTCH2 GSI-R/S* indicates the expression of the GSI-resistant/sensitive DNA-bound NOTCH2/CSL complexes.